Search

Your search keyword '"Ben Barouch, Sharon"' showing total 13 results
Start Over Author "Ben Barouch, Sharon"
13 results on '"Ben Barouch, Sharon"'

4. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

Author

Lackraj, Tracy, primary, Ben Barouch, Sharon, additional, Medeiros, Jessie J. F., additional, Pedersen, Stephanie, additional, Danesh, Arnavaz, additional, Bakhtiari, Mehran, additional, Hong, Michael, additional, Tong, Kit, additional, Joynt, Jesse, additional, Arruda, Andrea, additional, Minden, Mark D., additional, Kuruvilla, John, additional, Bhella, Sita, additional, Kukreti, Vishal, additional, Crump, Michael, additional, Prica, Anca, additional, Chen, Christine, additional, Deng, Yangqing, additional, Xu, Wei, additional, Pugh, Trevor J., additional, Keating, Armand, additional, Dick, John E., additional, Abelson, Sagi, additional, and Kridel, Robert, additional

Published
2022
Full Text
View/download PDF

6. Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

Author

Ben Barouch, Sharon, primary, Lackraj, Tracy, additional, Medeiros, Jessie, additional, Bakhtiari, Mehran, additional, Joynt, Jesse, additional, Tong, Kit, additional, Arruda, Andrea, additional, Minden, Mark D., additional, Alvarez, Mileidys, additional, Kuruvilla, John, additional, Bhella, Sita, additional, Kukreti, Vishal, additional, Crump, Michael, additional, Prica, Anca, additional, Chen, Christine I., additional, Keating, Armand, additional, Dick, John E., additional, Abelson, Sagi, additional, and Kridel, Robert, additional

Published
2021
Full Text
View/download PDF

7. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Author

Levy, Ilana, primary, Lavi, Avital, additional, Zimran, Eran, additional, Grisariu, Sigal, additional, Aumann, Shlomzion, additional, Itchaki, Gilad, additional, Berger, Tamar, additional, Raanani, Pia, additional, Harel, Reut, additional, Aviv, Ariel, additional, Lavi, Noa, additional, Zuckerman, Tsila, additional, Shvidel, Lev, additional, Jarchowsky, Osnat, additional, Ellis, Martin, additional, Herzog Tzarfati, Katrin, additional, Koren-Michowitz, Maya, additional, Sherf, Yehonatan, additional, Levi, Itai, additional, Sofer, Orit, additional, Shpilberg, Ofer, additional, Dally, Nagib, additional, Suriu, Celia, additional, Braester, Andrei, additional, Ben Barouch, Sharon, additional, Leiba, Merav, additional, Goldstein, Daniela, additional, Sarid, Nadav, additional, Yeganeh, Shay, additional, Halloun, Jabour, additional, Mittelman, Moshe, additional, and Tadmor, Tamar, additional

Published
2021
Full Text
View/download PDF

10. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

Author

Perry, Chava, primary, Ben Barouch, Sharon, additional, Goldschmidt, Neta, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Shvidel, Lev, additional, Bairey, Osnat, additional, Lavi, Noa, additional, Horowitz, Netanel, additional, Avigdor, Avraham, additional, Lebel, Eyal, additional, Sofer, Orit, additional, Ram, Ron, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

11. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)

Author

Ben-Barouch, Sharon and Kuruvilla, John

Abstract

ABSTRACTIntroduction: Selinexor is a first-in-class, oral therapeutic that selectively inhibits nuclear export. It has received fast track designation from the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) recently, and continues to be evaluated as a potential treatment for DLBCL.Area covered: This article reviews the available data from clinical trials regarding the efficacy of selinexor in DLBCL and highlights the key toxicity issues and how they may best be managed. Ongoing and future studies in DLBCL are also discussed.Expert opinion: More translational studies are necessary to leverage the unique mechanism action and rationally inform the use of selinexor in combination strategies. There are several different genetic subtypes of DLBCL, but it is not clear if these classifications will identify patients that may benefit from targeted therapies. The broad potential mechanism of action of selinexor will require careful analysis to inform predictive or prognostic biomarkers. Further evaluation of selinexor in combination with standard lymphoma regimens could identify deliverable promising regimens. Future randomized trials are key for registration and to determine the optimal role for this first-in-class agent.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results